Table 2.
Study outcomes
| End point | All patients (n=90) |
MRD (n=47) |
UCB (n=43) |
P-value1 |
|---|---|---|---|---|
| 3-year PFS (95% CI) | 32% (22-43) | 30% (16-44) | 34% (19-48) | 0.98 |
| 3-year OS (95% CI) | 39% (28-50) | 43% (29-58) | 34% (17-50) | 0.57 |
| Sustained donor engraftment at 42 days (95% CI)2,3 | 95% (93-97) | 100% | 89% (80-99) | 0.05 |
| Grade 2-4 acute GVHD (95% CI)2 | 45% (34-47) | 42% (27-57) | 49% (32-65) | 0.20 |
| Chronic GVHD at 1 year (95% CI)2 | 29% (18-40) | 40% (23-56) | 17% (5-29) | 0.02 |
| 180-day TRM (95% CI)2 | 26% (16-35) | 23% (11-36) | 28% (14-41) | 0.36 |
MRD — matched related donor; UCB — unrelated umbilical cord blood donor; TRM — transplant related mortality; GVHD — graft-versus-host disease; PFS — progression free survival; OS — overall survival; CI — confidence intervals
1
P-value for comparison between MRD and UCB
2
Cumulative incidence
3
Ten patients (MRD=5, UCB=5) were censored for engraftment analysis because of death prior to analysis for donor chimerism